Corcept Therapeutics' Relacorilant Combo Therapy Shows Clinical Benefit In Ovarian Cancer - Corcept Thera

Corcept Therapeutics Incorporated (NASDAQ:CORT) has announced that data from the Phase 2 trial of relacorilant plus nab-paclitaxel were presented at the European Society for Medical Oncology (ESMO21) Congress 2021.
The trial included 178 patients with recurrent platinum-resistant ovarian cancer.
Women who received the higher dose of relacorilant (150 mg) intermittently exhibited a statistically significant improvement in median progression-free survival (PFS) compared to those who received nab-paclitaxel alone (median PFS: 5.6 months versus 3.8 months).
The women in the Intermittent arm also experienced a statistically significant improvement in the duration of response (DoR) relative to those in the Comparator arm (median DoR: 5.6 months versus 3.7 months).
But the Company reported the median overall survival (OS) of 12.9 months versus 10.4 months in the Comparator arm.
Corcept will begin a pivotal Phase 3 trial in Q1 of 2022.
Price Action: CORT shares are down 1.94% at $20.23 during the market session on the last check Friday.
Check out our coverage of the European Society for Medical Oncology Congress (ESMO21).

To add Benzinga News as your preferred source on Google, click here.